0000000000323975

AUTHOR

Peter Diem

showing 3 related works from this author

Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis

2008

Objective To compare the effectiveness and safety of three types of stents (sirolimus eluting, paclitaxel eluting, and bare metal) in people with and without diabetes mellitus. Design Collaborative network meta-analysis. Data sources Electronic databases (Medline, Embase, the Cochrane Central Register of Controlled Trials), relevant websites, reference lists, conference abstracts, reviews, book chapters, and proceedings of advisory panels for the US Food and Drug Administration. Manufacturers and trialists provided additional data. Review methods Network meta-analysis with a mixed treatment comparison method to combine direct within trial comparisons between stents with indirect evidence fr…

medicine.medical_specialtyPaclitaxelmedicine.medical_treatment030204 cardiovascular system & hematologyCoronary Restenosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBlood vessel prosthesisInternal medicinemedicineHumans030212 general & internal medicinecardiovascular diseasesGeneral Environmental ScienceRandomized Controlled Trials as TopicSirolimusbusiness.industryResearchHazard ratioGeneral EngineeringDrug-Eluting StentsGeneral Medicineequipment and supplies3. Good healthSurgeryBlood Vessel ProsthesisProsthesis FailureClinical trialsurgical procedures operativePaclitaxelchemistryDrug-eluting stentMeta-analysisSirolimusGeneral Earth and Planetary SciencesPlatelet aggregation inhibitorStentsbusinessDiabetic AngiopathiesPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2…

2008

To assess the effects of pioglitazone and rosiglitazone on fasting and postprandial low-density lipoprotein (LDL) size and subclasses in patients with Type 2 diabetes.Nine Type 2 diabetic patients (age 61 +/- 10 years, body mass index 30 +/- 5 kg/m(2), glycosylated hemoglobin [HbA1c] 7.5 +/- 0.5%) were randomized in a crossover trial to rosiglitazone 4 mg b.i.d. or pioglitazone 45 mg/day for 12 weeks with an 8-week wash-out period. LDL size and subclasses were determined by non-denaturing polyacrylamide gradient gel electrophoresis. A standardized breakfast was served and variables were assessed after 3 and 6 h.HbA1c, insulin sensitivity (as assessed by the homeostasis model assessment) and…

Malemedicine.medical_specialtyType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsPharmacology (medical)Prospective StudiesTriglyceridesPharmacologyGlycated HemoglobinCross-Over StudiesTriglyceridePioglitazoneCholesterolbusiness.industryGeneral MedicineCholesterol LDLFastingGlucose Tolerance TestMiddle Agedmedicine.diseasePostprandial PeriodLipoproteins LDLPostprandialEndocrinologychemistryDiabetes Mellitus Type 2Low-density lipoproteindense LDL diabetes LDL size pioglitazone postprandial rosiglitazoneElectrophoresis Polyacrylamide GelFemaleThiazolidinedionesbusinessRosiglitazonePioglitazonemedicine.drug
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct